Curebase Secures Jane Myles as Vice President of Clinical Trial Innovation

Curebase’s decentralized clinical trial platform and model focuses on expanding clinical trial access to patients, by allowing them to participate in studies at-home, in their community, and with their own doctors. Curebase’s platform is an all-in-one decentralized clinical trial software system (ePRO, eConsent, eSource, Telemedicine, etc.) with a unique focus on engaging research naive providers, and points of care, in places traditional studies do not reach. Additionally, the company’s “Virtual Research Sites” also provide physicians with new and unique options to offer their patients, regardless of location by a establishing the resources of a research site in places where a physical site does not exist. Except these sites have much greater reach and move convenient options for patients to participate in clinical trials at home and in their community. The Curebase platform empowers sponsors, CROs and physicians from practices of all sizes to conduct clinical research, including private practices, independent clinics, and large academic research sites.

Throughout her career Myles has worked on evolving the clinical research process at a variety of levels while striving to make a more patient-centric approach. Undertaking those same challenges with Curebase, she will be responsible for developing, maintaining and promoting the company’s decentralized clinical trial (DCT) framework, assembling patient and physician advisory boards, establishing academic and key opinion leader partnerships, driving clinical trial design innovation, ensuring other Curebase teams are deploying the DCT framework, supporting sales to potential customers, and advocating for better patient-centricity.

“Jane’s deep knowledge of clinical operations and extensive experience designing and executing global registrational trials and leading global teams to solve trial recruitment and retention challenges will help Curebase’s DCT platform become even more patient-centric,” said Tom Lemberg, founder and chief executive officer of Curebase. “She demonstrates a strong passion for making clinical trials efficiently patient- and site-friendly, ultimately leading to better drug studies that benefit customers and patients.”

Immediately prior to joining Curebase, Myles served as the director of decentralized trials at Covance, where she led the design and optimization of the company’s decentralized trials delivery process as well as development and implementation of its operational strategy to drive broader adoption of decentralized and hybrid trials. She also spent more than 10 years at Roche as global head of patient recruitment and then as Head of Operational Intelligence and Innovation. Myles also had several clinical trial management leadership positions at Genentech, as well as other major pharmaceutical sponsors.

“What excites me about joining Curebase is that the company wants to take on the most difficult trials,” Myles said. “We want to make our trials accessible to the toughest cases like oncology and gene therapy patients because those are the patients who are most at risk, most immune-compromised, most sick, and most in need of support from caregivers, in addition to standing the most to benefit from a clinical trial.”

Myles received her Master’s degree in pharmacology and toxicology and bachelor’s degree in life sciences from Queen’s University in Ontario, Canada.

About Curebase

At Curebase, our mission is to bring quality medical innovations to patients faster and improve human wellbeing through more efficient clinical studies. We are proving that clinical research can be radically accelerated if we empower physicians everywhere to enroll patients in the communities where they live. By applying cutting edge clinical software and remote study management techniques to the problem, we are reinventing clinical trials and research from the ground up. For more information, please visit www.curebase.com.

Media Contact:

Shawn Malloy

media@curebase.com

315-882-5310

Related Links:

Original Article

SOURCE Pharma Voice

https://www.curebase.com

Press Releases

See More

Article Title

It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing.

Entire article

Article Title

It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing.

Entire article

Remote Care Powered CURE-19 Platform Enables At Home COVID-19 Clinical Trials

Curebase launches the CURE-19 Platform to provide a resource for researchers seeking to better understand COVID-19 as the pandemic begins

Entire article

Introducing ‘BYOP’ clinical trials

The company Curebase is promoting the concept of 'bring-your-own-physician' clinical trials.

Entire article

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

NEW YORK – Cofactor Genomics said Tuesday that it has commenced the first multicenter clinical trial of its OncoPrism immunotherapy response prediction assay, an RNA-based test developed using the company's proprietary immune modeling technology.

Entire article

Startups Cash In as Venture Funding for Digital Health Rises

The success of Doximity, which went public in June and now has a market capitalization around $8.87 billion, and other digital-health startups have encouraged venture investment.

Entire article

Preliminary Outcomes of a Digital Therapeutic Intervention for Smoking Cessation in Adult Smokers: Randomized Controlled Trial

Tobacco smoking remains the leading cause of preventable death and disease worldwide. Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness.

Entire article

CLM tests drug plus digital combo for high blood pressure

UK biotech Closed Loop Medicine (CLM) has started recruiting patients into a trial that will test whether a drug linked to a smartphone app can improve treatment for hypertension.

Entire article

Non-Traditional Clinical Trial Sites Powered by the Curebase System Support Emergency Use Authorization of New Rapid COVID-19 Test

Operationalizing drive-through COVID testing locations as clinical research sites provided a safe and convenient way to enroll and consent potential participants in key diagnostic validation study

Entire article

Curebase, InBios Announce Results of Virtual Clinical Trial of InBios COVID-19 Rapid Detection Test Using Curebase Platform

Study demonstrates efficacy of InBios diagnostics test, Curebase decentralized trials platform

Entire article

Curebase Names Paul Donnelly as Senior Vice President of Enterprise Strategy

Industry veteran brings more than two decades of success building healthcare companies

Entire article

Curebase nabs $15M for siteless trials that revolve 'around the patient's lifestyle'

Curebase has raised a $15 million series A for a new approach to decentralized trials that goes beyond the current drop of virtual trial platforms.

Entire article

Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical Study Access

Initial study will validate effectiveness of Adaptive's Lyme disease immune detection test

Entire article

Press Releases

See more

Introducing ‘BYOP’ clinical trials

The company Curebase is promoting the concept of 'bring-your-own-physician' clinical trials.

Entire article

Curebase Names Paul Donnelly as Senior Vice President of Enterprise Strategy

Industry veteran brings more than two decades of success building healthcare companies

Entire article

Startups Cash In as Venture Funding for Digital Health Rises

The success of Doximity, which went public in June and now has a market capitalization around $8.87 billion, and other digital-health startups have encouraged venture investment.

Entire article

Curebase, InBios Announce Results of Virtual Clinical Trial of InBios COVID-19 Rapid Detection Test Using Curebase Platform

Study demonstrates efficacy of InBios diagnostics test, Curebase decentralized trials platform

Entire article

Curebase nabs $15M for siteless trials that revolve 'around the patient's lifestyle'

Curebase has raised a $15 million series A for a new approach to decentralized trials that goes beyond the current drop of virtual trial platforms.

Entire article

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

NEW YORK – Cofactor Genomics said Tuesday that it has commenced the first multicenter clinical trial of its Onco Prism immunotherapy response prediction assay, an RNA-based test developed using the company's proprietary immune modeling technology.

Entire article

Non-Traditional Clinical Trial Sites Powered by the Curebase System Support Emergency Use Authorization of New Rapid COVID-19 Test

Operationalizing drive-through COVID testing locations as clinical research sites provided a safe and convenient way to enroll and consent potential participants in key diagnostic validation study

Entire article

CLM tests drug plus digital combo for high blood pressure

UK biotech Closed Loop Medicine (CLM) has started recruiting patients into a trial that will test whether a drug linked to a smartphone app can improve treatment for hypertension.

Entire article

Preliminary Outcomes of a Digital Therapeutic Intervention for Smoking Cessation in Adult Smokers: Randomized Controlled Trial

Tobacco smoking remains the leading cause of preventable death and disease worldwide. Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness.

Entire article

Curebase Secures Jane Myles as Vice President of Clinical Trial Innovation

Curebase, a company committed to democratizing access to clinical studies through decentralized clinical trials, has named tenured clinical research expert Jane Myles as vice president of clinical trial innovation

Entire article

Curebase, Adaptive Biotechnologies Announce Collaboration to Expand Clinical Study Access

Initial study will validate effectiveness of Adaptive's Lyme disease immune detection test

Entire article

Introducing ‘BYOP’ clinical trials

The company Curebase is promoting the concept of 'bring-your-own-physician' clinical trials.

Entire article

Curebase Names Paul Donnelly as Senior Vice President of Enterprise Strategy

Industry veteran brings more than two decades of success building healthcare companies

Entire article

Startups Cash In as Venture Funding for Digital Health Rises

The success of Doximity, which went public in June and now has a market capitalization around $8.87 billion, and other digital-health startups have encouraged venture investment.

Entire article

Curebase, InBios Announce Results of Virtual Clinical Trial of InBios COVID-19 Rapid Detection Test Using Curebase Platform

Study demonstrates efficacy of InBios diagnostics test, Curebase decentralized trials platform

Entire article

Curebase nabs $15M for siteless trials that revolve 'around the patient's lifestyle'

Curebase has raised a $15 million series A for a new approach to decentralized trials that goes beyond the current drop of virtual trial platforms.

Entire article

Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay

NEW YORK – Cofactor Genomics said Tuesday that it has commenced the first multicenter clinical trial of its OncoPrism immunotherapy response prediction assay, an RNA-based test developed using the company's proprietary immune modeling technology.

Entire article

Non-Traditional Clinical Trial Sites Powered by the Curebase System Support Emergency Use Authorization of New Rapid COVID-19 Test

Operationalizing drive-through COVID testing locations as clinical research sites provided a safe and convenient way to enroll and consent potential participants in key diagnostic validation study

Entire article

CLM tests drug plus digital combo for high blood pressure

UK biotech Closed Loop Medicine (CLM) has started recruiting patients into a trial that will test whether a drug linked to a smartphone app can improve treatment for hypertension.

Entire article

Preliminary Outcomes of a Digital Therapeutic Intervention for Smoking Cessation in Adult Smokers: Randomized Controlled Trial

Tobacco smoking remains the leading cause of preventable death and disease worldwide. Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness.

Entire article

Remote Care Powered CURE-19 Platform Enables At Home COVID-19 Clinical Trials

Curebase launches the CURE-19 Platform to provide a resource for researchers seeking to better understand COVID-19 as the pandemic begins

Entire article

Our latest news

It was popularised in the 1960s with the release of Letraset sheets containing Lorem Ipsum passages, and more recently with desktop publishing software like Aldus PageMaker including versions of Lorem Ipsum.

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
335 S Van Ness Ave, San Francisco, CA,
94103-3627, United States